Wall Street Wizardry
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Wall Street Wizardry

World News

Colombian presidential hopeful Miguel Uribe shot in Bogota

by admin June 8, 2025
June 8, 2025
Colombian presidential hopeful Miguel Uribe shot in Bogota

Colombian senator Miguel Uribe, in the running to join next year’s presidential race, has been shot at an event in Bogota, according to national police.

The mayor of Bogota, Carlos Galán, said Uribe was receiving emergency care after being attacked in the Fontibon district on Saturday and that the “entire hospital network” of the Colombian capital was on alert in case he needed to be transferred.

The mayor added that the suspected attacker had been arrested.

Colombian President Gustavo Petro expressed his solidarity with the senator’s family in a tweet on X, saying, “I don’t know how to ease your pain. It is the pain of a mother lost, and of a wounded homeland.”

Colombia’s government has issued a statement condemning the attack on Uribe.

This is a developing story and will be updated.

This post appeared first on cnn.com

previous post
Desperate to get its illegally detained civilians out of Russia, Kyiv offers Ukrainian collaborators in exchange
next post
Israel says it has killed leader of Palestinian militant group that took part in October 7 attack

Related Posts

No doctors for sick children. This is the...

February 12, 2025

Trump says the US needs to protect Greenland...

May 6, 2025

Hong Kong’s oldest pro-democracy party is shutting down...

April 20, 2025

‘It’s like a constant gamble:’ Ukrainian couple await...

February 1, 2025

Man wrongfully jailed for nearly four decades weeps...

May 14, 2025

Germany is unlocking billions to supercharge its military...

March 23, 2025

US and Russia to appoint teams to negotiate...

February 19, 2025

Yemen’s Houthis claim dozens killed in alleged US...

April 28, 2025

Accounts of child survivors shed light on surge...

March 14, 2025

Hamas and Israel trade blame over deal violations....

January 26, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 26, 2025
    • 2

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 3

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 4

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 5

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 6

      US security contractor will take charge of key checkpoint in Gaza as Israeli forces withdraw

      January 25, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: wallstreetwizardry.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 wallstreetwizardry.com | All Rights Reserved